Loading...
•
Jun 30, 2023
PMV Pharma Q2 2023 Earnings Report
PMV Pharmaceuticals reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
Key Takeaways
PMV Pharmaceuticals reported its Q2 2023 financial results, highlighting continued progress in the PYNNACLE study of PC14586 and a successful End-of-Phase 1 FDA meeting. The company ended the quarter with $218.8 million in cash, cash equivalents, and marketable securities.
Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586.
Concluded successful End-of-Phase 1 FDA meeting with alignment on recommended Phase 2 dose.
Ongoing enrollment in combination arm of PYNNACLE study with PC14586 and KEYTRUDA® (pembrolizumab).
Appointed Dr. Masha Poyurovsky as Vice President of Biology.
Forward Guidance
The company anticipates initiating the single arm, Phase 2 portion of the PYNNACLE study in early 2024 and sharing updated Phase 1 data in the second half of the year.
Positive Outlook
- Alignment with the FDA was obtained on the recommended Phase 2 dose.
- Key elements of the Phase 2 registrational portion of the PYNNACLE trial were aligned.
- Plans to initiate the single arm, Phase 2 portion of the PYNNACLE study in early 2024.
- Ongoing enrollment in the combination arm of PYNNACLE evaluating PC14586 with KEYTRUDA.
- Company will share updated Phase 1 data in the second half of the year.
Challenges Ahead
- Success of clinical trials are subject to risks and uncertainties.
- Ability to execute on its strategy and operate as an early clinical stage company is uncertain.
- Clinical trials of PC14586 or any future clinical trials of other product candidates may differ from preclinical, preliminary or expected results.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...